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Summary.-Rubidazone, the new semi-synthetic benzol hydrazone hydrochloride
derivative of daunorubicin, has proved on a molecular weight basis to be less toxic
than adriamycin and similar to daunorubicin in cardiac toxicity studies in the
hamster as well as in other in vivo and in vitro test systems. It has proven effective-
ness against several animal tumours and human acute leukaemias. We have
compared the inhibitory effect ofrubidazone to that of adriamycin on P388 leukaemia
and normal bone marrow colony-forming units (CFU) using the spleen colony
assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes
of the normal bone marrow CFU to leukaemic CFU dose-survival curves) in the
spleen colony assay system for rubidazone and adriamycin were 7-8 and 7*5 respect-
ively. This near identity of efficacy ratios for rubidazone and adriamycin correlated
with the results of median survival time studies in the leukaemic mice. Their
dose-mediap survival time curves were almost parallel, having nearly identical
slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the
spleen colony assay system together with its known decreased toxicity to cardiac
muscle cell' makes it an extremely promising new anthracycline derivative to
study in comparison to adriamycin in human malignancies.
RUBIDAZONE, the new semi-synthetic
benzol hydrazone hydrochloride derivative
of daunorubicin, isolated by the Rhone-
Poulenc Research Laboratory, has proven
effectiveness against a variety of experi-
mental tumours (Maral, Ponsinet and
Jolles, 1972) and human acute myelo-
blastic and lymphoblastic leukaemias
(Jacquillat et al., 1972; Bernard et al.,
1972). Although it appears to have
similar activity to adriamycin against
several mouse tumours (Johnson, 1974),
on an equal weight basis rubidazone
has been shown to cause less cardio-
toxicity than adriamycin in the hamster
(Maral et al., 1972) and rabbit (Young,
1974).
We have used the spleen colony
assay system for leukaemic and normal
bone marrow colony-forming units (CFU)
to compare the therapeutic index of
rubidazone with that of adriamycin, the
presently most active anthracycline com-
pound against a wide variety of human
solid malignancies (Blum and Carter,
1974). It was our belief at the initiation
of this study that if rubidazone was as
active as adriamycin against leukaemic
stem cells and showed the same or less
evidence of bone marrow damage, it
* Present address (to which requests for reprints should be addressed): Section of Hematology and
Oncology, Department of Internal Medicine, College of Medicine, University of Arizona, Tucson, Arizona
85724.
t Present address: Department of Microbiology, University of California, School of Medicine, San
Francisco, California 94143.DIFFERENTIAL TOXICITY IN THE SPLEEN COLONY ASSAY SYSTEM
might prove to be a worthwhile drug for
further clinical studies.
MATERIALS AND METHODS
Mice.-Six- to eight-week-old male DBA2
mice (Jackson Laboratories, Bar Harbor,
Maine) weighing approximately 25 g were
used in these experiments.
Mouse tumour line.-P388 lymphocytic
leukaemia was supplied by Dr John Harris
(Department of Radiobiology, University
of California, San Francisco) and serially
transplanted as an ascites tumour at weekly
intervals (105 cells every 7 days in medium
199) (GIBCO, Sunnyvale, California). It
was selected for these studies because it
predicts the clinical efficacy of anticancer
drugs more accurately than other mouse
tumour lines (Venditti, 1974).
Chemotherapeutic agents.-Rubidazone in
powder form (supplied by the Rhone-
Poulenc Industries, Paris, France by R.
Maral) was dissolved in sterile water to the
desired concentration. The powder was
stored in the dark at room temperature.
Thin layer chromatography' revealed the
drug to be in a pure form without significant
metabolites. Adriamycin (Adria Labora-
tories, New Jersey) in powder form was
also dissolved in sterile water to the desired
concentration. Again, thin layer chromato-
graphy revealed a narrow band of the
parent compound without significant agly-
cone or other metabolite moieties.
LCFU assay.-The assay for leukaemic
colony forming units (LCFU) was carried
out in the following way: On Day 0, 106
P388 cells were injected into the tail veins
of 5 groups of 5 DBA2 mice. In 4 of these
groups, adriamycin (at 4-9 mg/kg) or rubid-
azone (at 12-18 mg/kg) was injected i.p.
48 h (Day 2) after tumour cell injection
(when the i.p. P388 tumour had attained
a 93-+% growth fraction) (Harris, Shon and
Meneses, 1973). Both adriamycin and ru-
bidazone were injected in a constant volume
of 0.01 ml/g body wt. On Day 5 the mice
were sacrificed, femurs were isolated, and
bone marrow cells were washed out with
medium 199. Appropriate dilutions of fe-
moral bone marrow cells were injected in
0-2-ml volumes into the tail veins of groups
of 15-20 recipient mice. Nine days later
these recipient mice were sacrificed, spleens
removed and fixed in Bouin's solution, the
macroscopic LCFU were counted using a
dissecting microscope, and the fraction of
surviving LCFU per femur (as compared to
the controls) determined.
NCFU assay.-Normal bone marrow
colony forming units (NCFU) were assayed
in a similar way as LCFU except for the
following: 3 days after therapy with i.p.
adriamycin (at 4-15 mg/kg) or rubidazone
(at 15-40 mg/kg) 5 groups of 5 DBA2 mice
(including one control group) were sacrificed
and appropriate dilutions of normal femoral
bone marrow cells were injected i.v. into
groups of 15-20 whole-body-irradiated (720
rad from a 250-kV source) nmice. Nine days
later these mice were sacrificed, spleens were
removed and fixed in Bouin's solution, the
macroscopic NCFU were counted using a
dissecting microscope, and the fraction of
surviving NCFU per femur (as compared to
the controls) determined.
Meant saroival time studies-.Groups of
7 DBA2 mice were given 106 P388 ascites
cells i.v. in a volume of 0-2 ml and the mean
survival times of each of the control and
treatment groups was calculated by observing
for death at 12-h intervals. The administra-
tion schedule of adriamycin and rubidazone
was similar to that for the LCFU and NCFU
assays.
Statistical analysis.-A simple t test was
used to determine statistical significance
between the different experimental groups.
Dose-response curves for both adriamycin
and rubidazone with respect to LCFU and
NCFU were constructed on the basis of
regression analysis.
RESULTS
We have determined the effect of
rubidazone and adriamycin on the survival
of both normal bone marrow and leuk-
aemic CFU. Increasing doses of these
agents were administered as single i.p.
injections to groups of 5 mice and 3 days
later the femoral bone marrow cells were
assayed for their content of either normal
or leukaemic colony forming stem cells.
Results obtained with rubidazone and
adriamycin are shown in Fig. 1 and 2,
respectively, in which the surviving frac-
tion per femur of both normal and
leukaemic CFU is plotted as a function
of the dose of drug injected. As plotted
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FIG. 1.-Rubidazone dose-response curves
for leukaemic (L) and normal bone marrow
(N) colony forming units (CFU) in the
mouse spleen colony assay system. Each
point represents the mean±s.e. for 15-20
mice.
in semi-logarithmic form, the dose-re-
sponse curves for both leukaemic and
normal bone marrow CFU for both
rubidazone and adriamycin were ex-
ponential. The fraction ofsurviving leuk-
aemic or normal CFU per mouse femur
were not significantly different when
assayed 1 or 3 days after the administra-
tion ofeither rubidazone or adriamycin.
In order to define either rubidazone's
or adriamycin's differential effect on
leukaemid- versus normal bone marrow
colony forming units, we have used the
term " effipacy ratio " of Valeriote and
Tolen (1972), which is simply the ratio
of the slopes of the two dose-survival
curves. We have also used Valeriote
and Tolen's D1/2 value as a measure
of the slope for both rubidazone and
adriamycin, calculated on the expo-
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FIG. 2.-Adriamycin dose-response curves for
leukaemic (L) and normal bone marrow (N)
CFU in the mouse spleen colony assay
system. Each point represents the mean
± s.e. for 15-20 mice.
nential portion of the dose response
curves. The D1/2 value is the dose of
drug which reduces the survival of the
cell population in question by a factor
of one-half. As seen in Fig. 1, the D1/2
of rubidazone for LCFU was 1 6 mg/kg;
whereas, for NCFU it was 12-4 mg/kg.
The resulting efficacy ratio of rubidazone
was 7-8 (i.e., 12.4/1.6, or 7.8). In Fig. 2,
it can be seen that the D1/2 of adriamycin
for LCFU was 0-85 mg/kg and for NCFU
6*4 mg/kg, resulting in an efficacy ratio
of 715. This near-identity of efficacy
ratios of rubidazone and adriamycin
is reflected in the results of the tumour-
bearing mouse survival studies with these
agents. In Fig. 3 the median survival
times of the DBA2 mice following ad-
ministration ofP388 leukaemia are plotted
against the dose in mg/kg of rubidazone
or adriamycin used for each of these
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FiG. 3.-Adriamycin V8. rubidazone dose-response survival time studies for P388 leukaemia in
DBA2 mice. Each point represents the mean i s.e. for 7 mice.
survival studies. Note that the two
survival-dose curves are almost parallel.
DISCUSSION
Rubidazone may be a more active
drug than adriamycin for the treatment
of acute myeloblastic leukaemia (Jacquil-
lat et al., 1972; Bernard et al., 1972;
Courts, Ellison and Yates, 1972; Klener,
Donner and Kojina, 1973). Bernard et
al. (1972) have reported 17 complete
remissions in 33 patients with acute
myeloblastic leukaemia treated with ru-
bidazone. The median dose to obtain
complete remission was 23 mg/kg and
there was evidence of congestive heart
failure only in patients who had had
prior daunorubicin therapy (Jacquillat,
1974). Although EKG changes were seen
in 9 of 21 rubidazone-treated patients
studied by Chauvergne and Durand
(1973), there was no evidence ofcongestive
heart failure in their study.
Young (1974) has presented data on
29 rabbits treated at the National Cancer
Institute for cardiac toxicity following
anthracycline administration. Dosage
schedules included rubidazone at 26-4
mg/M2; adriamycin, 7.7 mg/M2; and dau-
norubicin, 11 mg/M2 given three times
per week. The cardiotoxic dose for
rubidazone was 1560 mg/M2 compared
with 250 mg/M2 for adriamycin and 400
mg/i2 for daunorubicin. For the dosage
schedules employed, it took approxim-
ately 19x7 weeks to reach the critical
cardiotoxic dose with rubidazone com-
pared to 10-8 weeks for adriamycin and
12-1 weeks for daunorubicin.
Using the spleen colony assay system
to determine the relative effects of
rubidazone or adriamycin on leukaemic
or normal bone marrow stem cell growth
characteristics, we have shown that these
two agents have very similar " efficacy
ratios ". Though on a mg/kg basis adria-
mycin appears to be more effective than
rubidazone in the inhibition of leukaemic
CFU, when balanced with the effects on
normal bone marrow CFFU, this seeming
advantage of adriamycin is cancelled
out. Corroborating the results in the
spleen colony assay system are the
parallel dose-response curves with respect
to mean survival time studies for these
two anticancer drugs. If the animal
data of Young and the human data
of Jacquillat and Chauvergne for the
incidence of cardiotoxic effects following
rubidazone administration prove to be
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accurate, then the results of this study
indicating equal efficacy for the two
drugs with respect to tumour and normal
bone marrow stem cell inhibition suggest
that rubidazone could be clinically more
useful than adriamycin (Bernard et al.,
1972; Klener et al., 1973; Jacquillat,
1974). Certainly, our data along with
those of previously quoted investigators
suggest that rubidazone should be given
a thorough clinical trial to determine its
true efficacy and cardiotoxicity. Adria-
mycin has proved extremely useful in
the treatment ofa variety ofsolid tumours
and acute leukaemia (Blum and Carter,
1,974; Courts et al., 1972; Klener et al.,
1973); however, its utility is limited by
the advent ofcardiotoxicity at a relatively
low dosage (Lefrak et al., 1973). Because
of the cardiotoxic characteristics of adria-
mycin, much work now and in the
future is being carried out to identify
anthracycline-type drugs with equal or
greater clinical efficacy but less cardio-
toxicity. Rubidazone could prove to be
such a drug.
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